On Oct. 22, 2020, the World Health Organizationﾒs Global TB Programme welcomed the results from a landmark study on the treatment of drug-susceptible TB. The study, named Study 31/A5349, was led by the U.S. Centers for Disease Control and Preventionﾒs in collaboration with the AIDS Clinical Trials Group and funded by the National Institute of Allergy and Infectious Diseases.

Thirteen countries contributed data to the study, from 34 clinical sites. Approximately 2 500 people aged 12 years and older participated in the study, including 214 people living with HIV infection.